The aim of this placebo controlled double blind randomized clinical trial will be to evaluate the effect of vitamin D3 supplementation on chronic osteomyelitis treatment and on sleep quality, anxiety and depression in patients with chronic osteomyelitis. Inclusion criterion is patients with chronic osteomyelitis ranged in age from 16 to 55 years old. The main exclusion criteria are concurrent other vitamin D supplements use during the study and use of immunosuppressants . A total of 50 patients will be recruited from clinic. These patients will be divided into two groups (intervention and placebo), each have 25 patients, using block randomization. After signing informed consent form by patients, vitamin D3 will be administered 200000 units at baseline and 100000 units after one, two, three, four and five months in intervention group and patients will take placebo with the same dose and frequency in placebo group. Depression, anxiety, and sleep quality will be evaluated using self-reported questionnaires at baseline, after 3 and 6 months. Clinical presentations, ESR, and CRP will be also evaluated at baseline and after 2 weeks, one, two, three, four, five and six months.